• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Chronic Obstructive Pulmonary Disease (COPD) Market: An Analysis Product Image

Chronic Obstructive Pulmonary Disease (COPD) Market: An Analysis

  • Published: May 2009
  • Region: World
  • 35 Pages
  • Koncept Analytics

FEATURED COMPANIES

  • AstraZeneca plc
  • Glaxo Smith Kline
  • Merck & Co.
  • MORE

In the present era, use of tobacco, polluted environment, poverty and aging population have become a major threat; all these factors account for a major cause of deaths by COPD. Market for COPD medication is growing with increasing prevalence rate worldwide and it has become the fourth leading cause of death. The number of people with COPD varies throughout world. Cape Town has the highest prevalence of COPD, while Hanover has the lowest prevalence.

In United States, its prevalence is high and geographically, its prevalence in the Southern part of the country is highest and the Northeastern part has the lowest prevalence rate. With increasing rate of COPD patients, the economic cost is also increasing, which leads to the highest economic cost out of all the lung diseases in United States.

Spiriva is the leading medication for the disease while rest of the medicines market is expected to decline in future with the effect of new developments and increasing competition. At present Advair has also a good hold in the market. Inhalers demand is high for COPD and there are few oral medicines available.

The present report analyses worldwide COPD market with prevalence READ MORE >

1. COPD Industry: An Overview

2. Worldwide COPD Market

2.1 COPD Medication

Spiriva
Advair
Symbicort/ Pulmicort
Brovana
Xopenex

3. Prevalence and Mortality Rate of COPD

3.1 Prevalence in United States
3.2 Prevalence in Australia
3.3 Mortality Rate of COPD

4. Economic Cost

4.1 United States
4.2 Australia

5. Industry Analysis

5.1 Future Trends

Respiratory Medications Market
Prevalence Rate Continues to Grow

6. Growth Drivers

6.1 Indoor Air Pollutants
6.2 Occupational Exposure
6.3 Aging Population Leads to Surge in COPD
6.4 Smoking - A Leading cause of COPD
6.5 Air Pollution

7. Company Profiles

7.1 Glaxo Smith Kline

Overview
Business Strategies
Business and Product Expansion
Diversify Through Externalization
Re-Shape Manufacturing

7.2 AstraZeneca plc

Overview
Business Strategies
Diversified Areas of Research
Strong Presence in Emerging Markets

7.3 Merck & Co.

Overview
Business Strategies
Rolling Out a Customer-Centric Selling Model

8. Market Outlook

8.1 Market Forecast
8.2 Forecast Methodology

8.2.1 Dependent and Independent Variables
8.2.2 Correlation Analysis
8.2.3 Regression Analysis

List of Tables:

COPD Prevalence Rates by Age and Gender in Australia (2007)
Relative Risk of Mortality Due to COPD
Comparison of Costs Associated with COPD in Various Countries
COPD Cost by Type of Cost and Bearer in Australia (2008)
Value of Independent Variable (2002-08)
Correlation Table
Model Summary - Coefficient of Determination
Regression Table – Summary of Coefficients

List of Charts:

Total Respiratory Disease Market Comparison (2001-06)
Worldwide COPD Market by Value (2003-12E)
Spiriva Market Value and Forecast (2002-11E)
Advair Sales and Forecast (2007-13E)
Flixotide Sales and Forecast (2007-13E)
Symbicort/Pulmicort Revenue and Forecast (2007-13E)
Singulair Revenue and Forecast (2007-13E)
Market Share of HFA-Based Short Acting Beta Agonists (2006-07)
Chronic Bronchitis - Percentage Distribution by Gender (2007)
Prevalence by Geographic Region (2007)
Emphysema, Percentage Distribution by Gender (2007)
Prevalence of COPD in Australia (2008)
Economic Cost of Selected Lung Diseases in US (2007)
Distribution of COPD Cost (2007)
Financial Cost of COPD by Type of Cost (2007)
Expected Respiratory Market Size and COPD Share (2010-16E)
COPD by Severity, Projected Prevalence (2008-50E)
Worldwide Aging Population (2000-10E)
Worldwide Number of Smokers (2000-10E)
Worldwide Carbon Dioxide Emissions (2004-30E)
GSK Revenues (2006-08)
AstraZeneca Revenues by Geography (2006-08)
Merck Revenues by Business Segments (2006-08)
Worldwide COPD Market Forecast (2009-10E)

- Glaxo Smith Kline

- AstraZeneca plc

- Merck & Co.

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Hard Copy (Hard Back) A printed copy of the report will be shipped to you. The report has a hardback cover.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos